The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors
Mario Mandalà(University of Perugia), Marco Tucci(Prostate Cancer UK), Giuseppe Palmieri(University of Sassari), Daniela Massi(University of Florence), Roberta De Penni(University of Modena and Reggio Emilia), Barbara Valeri(Fondazione IRCCS Istituto Nazionale dei Tumori), Barbara Merelli(Ospedale Papa Giovanni XXIII), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Lorenza Di Guardo(Fondazione IRCCS Istituto Nazionale dei Tumori), Fabrizio Carnevale‐Schianca(Candiolo Cancer Institute), Laura Cattaneo(Ospedale Papa Giovanni XXIII), Mara Cossa(Fondazione IRCCS Istituto Nazionale dei Tumori), Gianna Baroni(University of Florence), Francesca Consoli(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Viviana Vallacchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Eliana Rulli(Mario Negri Institute for Pharmacological Research), Michele Guida(Istituto Tumori Bari), Francesca Portelli(Fondazione IRCCS Istituto Nazionale dei Tumori), Romina Nassini(University of Florence), Francesco De Logu(University of Florence), Pietro Quaglino(Department of Medical Sciences), Licia Rivoltini(Fondazione IRCCS Istituto Nazionale dei Tumori), Paola Queirolo, Marcella Occelli, Monica Rodolfo(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandro Marco Minisini, Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Anna Maria Di Giacomo(University of Siena)
Cited by 68
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k